D.T.I.C
Generic Name: Dacarbazine
Product Name: D.T.I.C
Indication
Darcarbazine is used in the treatment of the following tumours:
- Metastatic malignant melanoma
- Ewing’s sarcoma
- Rhabdomyosarcoma
- Hodgkin’s disease
Action
Dacarbazine interferes with cellular replication by forming cross-linkages between DNA strands.
Dose advice
Specialist protocols should be consulted concerning dosages:
Melanoma
- An initial dose that may be used is 250 mg/m2 daily given by intravenous infusion on days 1-5 of each 21-day cycle
- Alternatively, 800 mg/m2 can be given on day 1 of each 21-day cycle
- These doses may be used in single or combination therapy
- Subsequent doses depend on the individual patient’s response and the severity of adverse effects.
Hodgkin’s disease
- Dacarbazine is used in combination treatment with other antineoplastic agents
- 150 mg/m2 each day given by intravenous infusion on days 1-5 of each 28-day cycle
- Alternatively, 375 mg/m2 can be given on day 1 and day 15 of each 28-day cycle.
Schedule
S4
Common side effects
- Bone marrow suppression
- Nausea
- Vomiting
- Diarrhoea
- Fever
- Muscle aches
- Fatigue
- Facial flushing
- Pain along the injected vein
Uncommon side effects
- Low white cell count
- Blurred vision
- Hair loss
- Confusion
- Headache
- Rash
- Increased sensitivity of skin to light
- Seizures
For further information talk to your doctor.
Dates
Posted On: 22 July, 2003
Modified On: 20 November, 2015
Tags
Created by: